Top

Published in:

01-12-2018 | Clinical Study

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience

Authors: Cassie Kline, S. John Liu, Sai Duriseti, Anuradha Banerjee, Theodore Nicolaides, Shannon Raber, Nalin Gupta, Daphne Haas-Kogan, Steve Braunstein, Sabine Mueller

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Background

Diffuse intrinsic pontine glioma (DIPG) is a rare, aggressive brain tumor with no known cure. Reirradiation (reRT) at recurrence can prolong survival. The impact of irradiation may be heightened when combined with PD-1 inhibition. We describe our experience using reRT, with or without PD-1 inhibition, in a cohort of patients with recurrent DIPG.

Methods

We performed a retrospective cohort analysis of children who received reRT with or without concomitant PD-1 inhibition for recurrent DIPG at a single institution between 2005 and 2016. We compared progression-free (PFS) and overall survival (OS) between those who received reRT alone or in combination with PD-1 inhibition. We then compared reRT to a cohort of patients who did not receive reRT.

Results

Thirty-one patients were included (8—reRT with nivolumab; 4—reRT alone; 19—no reRT). Patients who received reRT had prolonged OS compared to no reRT (22.9 months—reRT with nivolumab; 20.4 months—reRT alone; 8.3 months—no reRT; p < 0.0001). Patients who received reRT with nivolumab vs. reRT only had slightly prolonged OS from diagnosis and from reRT (22.9 vs. 20.4 months for time from diagnosis; 6.8 vs. 6.0 months for time from reRT). All patients receiving reRT with or without nivolumab tolerated the therapy without acute or late toxicity.

Conclusions

Our experience demonstrates the tolerability of reRT with concurrent PD-1 inhibition for recurrent DIPG and suggests that combination therapy may offer survival benefit. Future prospective studies are needed to confirm the benefits of this combination therapy.

Allen J, Siffert J, Donahue B et al (1999) A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86:1064–1069CrossRefPubMed

Chintagumpala M, Gajjar A (2015) Brain tumors. Pediatr Clin North Am 62:167–178. https://doi.org/10.1016/j.pcl.2014.09.011 CrossRefPubMed

Cohen KJ, Broniscer A, Glod J (2001) Pediatric glial tumors. Curr Treat Options Oncol 2:529–536. https://doi.org/10.1007/s11864-001-0074-9 CrossRefPubMed

Kaye EC, Baker JN, Broniscer A (2014) Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis. CNS Oncol 3:421–431. https://doi.org/10.2217/cns.14.47 CrossRefPubMedPubMedCentral

Lam S, Lin Y, Auffinger B, Melkonian S (2015) Analysis of survival in pediatric high-grade brainstem gliomas: A population-based study. J Pediatr Neurosci 10:199–206. https://doi.org/10.4103/1817-1745.165656 CrossRefPubMedPubMedCentral

Packer RJ (1994) Diagnosis, treatment, and outcome of primary central nervous system tumors of childhood. Curr Opin Oncol 6:240–246CrossRefPubMed

Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248. https://doi.org/10.1016/S1470-2045(06)70615-5 CrossRefPubMed

Veldhuijzen van Zanten SEM, Jansen MHA, Sanchez Aliaga E et al (2015) A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther 15:157–164. https://doi.org/10.1586/14737140.2015.974563 CrossRef

Walston S, Hamstra DA, Oh K et al (2015) A multi-institutional experience in pediatric high-grade glioma. Front Oncol 5:28. https://doi.org/10.3389/fonc.2015.00028 CrossRefPubMedPubMedCentral

10.

Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9:197–206CrossRefPubMed

11.

Schild SE, Stafford SL, Brown PD et al (1998) The results of radiotherapy for brainstem tumors. J Neurooncol 40:171–177CrossRefPubMed

12.

Nazarian J, Mason GE, Ho CY et al (2016) Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget 7:42837–42842. https://doi.org/10.18632/oncotarget.10034 CrossRefPubMedPubMedCentral

13.

Sethi R, Allen J, Donahue B et al (2011) Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol 102:121–127. https://doi.org/10.1007/s11060-010-0301-y CrossRefPubMed

14.

Donahue B, Allen J, Siffert J et al (1998) Patterns of recurrence in brain stem gliomas: evidence for craniospinal dissemination. Radiation Oncology Biology 40:677–680CrossRef

15.

Wolff JE, Rytting ME, Vats TS et al (2012) Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol 106:391–397. https://doi.org/10.1007/s11060-011-0677-3 CrossRefPubMed

16.

Lassaletta A, Strother D, Laperriere N et al (2018) Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer 65:e26988. https://doi.org/10.1002/pbc.26988 CrossRefPubMed

17.

Miyazaki T, Ishikawa E, Matsuda M et al (2017) Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol 133:277–285. https://doi.org/10.1007/s11060-017-2451-7 CrossRefPubMed

18.

Garber ST, Hashimoto Y, Weathers S-P et al (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology 18:1357–1366. https://doi.org/10.1093/neuonc/now132 CrossRefPubMedPubMedCentral

19.

Berghoff AS, Kiesel B, Widhalm G et al (2015) Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology 17:1064–1075. https://doi.org/10.1093/neuonc/nou307 CrossRefPubMed

20.

Hwang K, Koh EJ, Choi EJ et al (2018) PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 54:307–311. https://doi.org/10.1007/s11060-018-2886-5 CrossRef

21.

Majzner RG, Simon JS, Grosso JF et al (2017) Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer 123:3807–3815. https://doi.org/10.1002/cncr.30724 CrossRefPubMed

22.

Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211. https://doi.org/10.1200/JCO.2016.66.6552 CrossRefPubMed

23.

Wainwright DA, Chang AL, Dey M et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290–5301. https://doi.org/10.1158/1078-0432.CCR-14-0514 CrossRefPubMedPubMedCentral

24.

Reardon DA, Gokhale PC, Klein SR et al (2016) Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4:124–135. https://doi.org/10.1158/2326-6066.CIR-15-0151 CrossRefPubMed

25.

Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498–e509. https://doi.org/10.1016/S1470-2045(15)00007-8 CrossRefPubMed

26.

Zeng J, See AP, Phallen J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86:343–349. https://doi.org/10.1016/j.ijrobp.2012.12.025 CrossRefPubMedPubMedCentral

27.

Hellmann MD, Friedman CF, Wolchok JD (2016) Combinatorial cancer immunotherapies. Adv Immunol 130:251–277. https://doi.org/10.1016/bs.ai.2015.12.005 CrossRefPubMed

28.

Kiess AP, Wolchok JD, Barker CA et al (2015) Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368–375. https://doi.org/10.1016/j.ijrobp.2015.01.004 CrossRefPubMedPubMedCentral

29.

Knisely JPS, Yu JB, Flanigan J et al (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227–233. https://doi.org/10.3171/2012.5.JNS111929 CrossRefPubMedPubMedCentral

30.

Fried I, Lossos A, Ben Ami T et al (2018) Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. J Neurooncol 136:189–195. https://doi.org/10.1007/s11060-017-2643-1 CrossRefPubMed

31.

Hwang EOA, Young-Poussaint T, Mitchell D et al (2018) Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a Pediatric Brain Tumor Consortium sutdy (PBTC045). In: International Society of Pediatric Neuro-Oncology; July 1–July 3, Denver, CO Abstract presented as IMMU-09

32.

Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133. https://doi.org/10.1056/NEJMoa1302369 CrossRefPubMedPubMedCentral

33.

Vlahovic G, Fecci PE, Reardon D, Sampson JH (2015) Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro-Oncol 17:1043–1045. https://doi.org/10.1093/neuonc/nov071 CrossRefPubMedPubMedCentral

34.

Trainer H, Hulse P, Higham CE et al (2016) Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-16-0108 CrossRefPubMedPubMedCentral

35.

Vandiver JW, Singer Z, Harshberger C (2016) Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol 11:553–556. https://doi.org/10.1007/s11523-016-0426-9 CrossRefPubMed

36.

Janssens GO, Gandola L, Bolle S et al (2017) Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73:38–47. https://doi.org/10.1016/j.ejca.2016.12.007 CrossRefPubMed

37.

Freese C, Takiar V, Fouladi M et al (2017) Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol 7:86–92. https://doi.org/10.1016/j.prro.2016.11.005 CrossRefPubMed

38.

Massimino M, Biassoni V, Miceli R et al (2014) Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol 118:305–312. https://doi.org/10.1007/s11060-014-1428-z CrossRefPubMed

39.

Fontanilla HP, Pinnix CC, Ketonen LM et al (2012) Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 35:51–57. https://doi.org/10.1097/COC.0b013e318201a2b7 CrossRefPubMed

40.

Castel D, Philippe C, Calmon R et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815–827. https://doi.org/10.1007/s00401-015-1478-0 CrossRefPubMedPubMedCentral

41.

Khuong-Quang D-A, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447. https://doi.org/10.1007/s00401-012-0998-0 CrossRefPubMedPubMedCentral

42.

Mandell LR, Kadota R, Freeman C et al (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Radiat Oncol Biol 43:959–964CrossRef

43.

Freeman CR, Krischer JP, Sanford RA et al (1993) Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Radiat Oncol Biol 27:197–206CrossRef

44.

Svolos P, Reddick WE, Edwards A et al (2017) Measurable supratentorial white matter volume changes in patients with diffuse intrinsic pontine glioma treated with an anti-vascular endothelial growth factor agent, steroids, and radiation. AJNR Am J Neuroradiol 38:1235–1241. https://doi.org/10.3174/ajnr.A5159 CrossRefPubMedPubMedCentral

45.

van den Bent MJ, Vogelbaum MA, Wen PY et al (2009) End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria. J Clin Oncol 27:2905–2908. https://doi.org/10.1200/JCO.2009.22.4998 CrossRefPubMedPubMedCentral

46.

Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113:232–241. https://doi.org/10.1038/bjc.2015.238 CrossRefPubMedPubMedCentral

47.

Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534–e542. https://doi.org/10.1016/S1470-2045(15)00088-1 CrossRefPubMedPubMedCentral

Title: Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience
Authors: Cassie Kline
S. John Liu
Sai Duriseti
Anuradha Banerjee
Theodore Nicolaides
Shannon Raber
Nalin Gupta
Daphne Haas-Kogan
Steve Braunstein
Sabine Mueller
Publication date: 01-12-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2991-5

At a glance: The STEP trials

Springer Medicine

Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

A comparative analysis of clinicopathological features and survival among early adolescents/young adults and children with low-grade glioma: a report from the Children’s Oncology Group

Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study

The importance of adequate methotrexate and adequate folinic acid rescue doses in the treatment of primary brain lymphoma

Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II–IV

Platelet count is associated with outcome in cancer patients with stroke